$BHC scripts in week to March 13th mostly down after a very strong prior week. so far in q1 we are looking at q/q growth of 16% for Trulance, 9% for Vyzulta, 1.9% for Relistor, -0.5% for Siliq and -4.2% for Xifaxan. There's some seasonality in sequential rates for the established products like Xifaxan - scripts are still growing about 1% (off a tough compare) on a y/y basis.
  • 17
  • 3